Showing 2431-2440 of 3315 results for "".
- The Vision Council Comments on Impact of Proposed Tariffs on Optical Industryhttps://modernod.com/news/the-vision-council-comments-on-impact-of-proposed-tariffs-on-optical-industry/2482880/The Vision Council has released a letter summarizing the recent tariffs proposed by the Trump administration and the impact it could have on the optical industry. The White House issued formal notice to several US trading partners outlining tariff
- Johnson & Johnson Appoints Kelly Heaps, Vice President of US Sales, Vision Carehttps://modernod.com/news/johnson-johnson-appoints-kelly-heaps-vice-president-of-us-sales-vision-care/2482879/Johnson & Johnson announced the appointment of Kelly Heaps as Vice President of US Sales, Vision Care. As the leader of the US Sales Organization, Ms. Heaps will work to accelerate sales and foster market share growth while collaborating with customers to strengthen patient outcomes.
- First Patient Dosed in the Phase 1 Trial of PulseSight Therapeutics’ Investigational PST-611 Treatment for Dry AMD/GAhttps://modernod.com/news/first-patient-dosed-in-the-phase-1-trial-of-pulsesight-therapeutics-investigational-pst-611-treatment-for-dry-amdga/2482874/PulseSight Therapeutics has announced that the first patient has been dosed in its phase 1 clinical trial (PST-611-CT1) assessing the safety and tolerability of its lead program, PST-611, in humans. PST-611 is a first-in-class non-viral vectorized
- Feliqs Secures $9 Million Series A to Advance FLQ-101 Clinical Trial for Retinopathy of Prematurityhttps://modernod.com/news/feliqs-secures-9-million-series-a-to-advance-flq-101-clinical-trial-for-retinopathy-of-prematurity/2482869/Feliqs Corp. announced the successful completion of a $9 million Series A financing round to advance the company's lead investigational therapy, FLQ-101, into clinical development. Designed as a once-daily oral or intravenous formulation, FLQ-101 aims
- Nicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical Trialhttps://modernod.com/news/nicox-announces-last-patient-completes-the-ncx-470-denali-phase-3-clinical-trial/2482865/Nicox SA announced the completion of patient treatment and follow-up in the Denali phase 3 clinical trial for NCX 470, its lead candidate for the treatment of open-angle glaucoma and ocular hypertension. In total, 696 p
- ForSight Robotics Secures $125 Million in Series B Fundinghttps://modernod.com/news/forsight-robotics-secures-125-million-in-series-b-funding-addressing-global-surgeon-shortage-and-demand-for-ophthalmic-surgery/2482862/ForSight Robotics announced it has completed a $125M Series B round, led by Eclipse. The investment accelerates the next growth phase for the ORYOM Platform, the world’s first robotic surgery platform for cataract and other eye diseases designed to enhance surgical precision, incr
- Qlaris Bio to Present New Clinical and Preclinical Data on QLS-111 at 2025 World Glaucoma Congresshttps://modernod.com/news/qlaris-bio-to-present-new-clinical-and-preclinical-data-on-qls-111-at-2025-world-glaucoma-congress/2482859/Qlaris Bio announced that new data from studies of its lead investigational compound QLS-111 will be presented at the 2025 World Glaucoma Congress (WGC). This will include an oral presentation on clinical data from the recently completed QC-111-201 “Osprey” and QC-111-203 “
- Alcon Introduces Clareon PanOptix Pro in Canadahttps://modernod.com/news/alcon-introduces-clareon-panoptix-pro-in-canada/2482857/Alcon announced the approval of Clareon PanOptix Pro IOL in Canada. According to Alcon, PanOptix Pro leverages the company's proprietary 'ENLIGHTEN NXT' optical technology, which delivers the lowest light scatter and highest reported light utilization of
- PolyActiva Appoints Jerry St. Peter as CEO; Secures Financing to Advance Prezia Technology Platformhttps://modernod.com/news/polyactiva-appoints-jerry-st-peter-as-ceo-secures-financing-to-advance-prezia-technology-platform/2482854/PolyActiva announced two milestones in its next phase of growth: the appointment of biopharmaceutical executive Jerry St. Peter as CEO and board director, and the successful close of a $25M Series C funding round led by an Australian Sovereign Wealth Fund
- Johnson & Johnson Launches Tecnis Odyssey IOL in Europe, the Middle East, and Canadahttps://modernod.com/news/johnson-johnson-launches-tecnis-odyssey-iol-in-europe-the-middle-east-and-canada/2482853/Johnson & Johnson announced that it is expanding its portfolio of presbyopia-correcting intraocular lenses (PC-IOL) with the roll-out of Tecnis Odyssey IOL in Europe, the Middle East, and Canada. According to J&J, the new full visual range IOL offers high-quality and c